Related Experiment Video
Updated: Oct 25, 2025
04:47
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
1.3K
Intestinal Microbial Metabolites in Ankylosing Spondylitis
Giuseppe Scalise1, Antonio Ciancio1, Daniele Mauro1
1Rheumatology Unit, Department of Precision Medicine, Università Degli Studi Della Campania L. Vanvitelli, 80138 Naples, Italy.
Journal of Clinical Medicine
|August 7, 2021
Summary
Ankylosing spondylitis (AS) involves gut dysbiosis impacting the immune system via the gut-joint axis. Microbial metabolites like short-chain fatty acids influence AS pathogenesis, offering potential therapeutic targets.
Area of Science:
- Immunology
- Microbiology
- Gastroenterology
Background:
- Ankylosing spondylitis (AS) is a chronic inflammatory axial disease.
- Intestinal dysbiosis is implicated in AS pathogenesis via the gut-joint axis.
- Mechanisms of gut-immune system cross-talk in AS remain unclear.
Purpose of the Study:
- To review the role of microbial metabolites in AS.
- To highlight short-chain fatty acids, tryptophan, and vitamin B derivatives.
- To discuss their impact on barrier integrity and type 3 immunity.
Main Methods:
- Literature review of studies on microbial metabolites and AS.
- Focus on short-chain fatty acids, tryptophan, and vitamin B derivatives.
- Analysis of their roles in gut barrier function and immune responses.
Main Results:
- Microbial metabolites significantly influence gut homeostasis and extraintestinal inflammation in AS.
- Short-chain fatty acids, tryptophan, and vitamin B derivatives modulate barrier integrity.
- These metabolites affect type 3 immunity, contributing to AS pathogenesis.
Conclusions:
- Microbial metabolites are key mediators in the gut-joint axis of AS.
- Understanding these metabolites can lead to novel therapeutic targets.
- Dietary interventions targeting microbial metabolism may ameliorate AS symptoms.
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
571
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
571
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
290
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
464
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
464
01:29Drugs for Treatment of Ulcerative Colitis in IBD
279
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
279
01:28Fungal Phylum Microsporidia
195
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
195
01:29Inflammatory Bowel Disease IV: Pharmacological Management
245
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
245